Gilead CAR-T’s indolent lymphoma data impresses at ASCO. How to position it is another question
Source: https://ift.tt/3dk8pZF
The company is seeking approval for Yescarta in follicular and marginal zone lymphomas. While it has a clear efficacy advantage over existing therapy options, experts said whether to use it in their place will entail complicated conversations with patients.
Source: https://ift.tt/3dk8pZF
0 Comments